Advertisement

Topics

Clinical Trials About "Safety Study of PLX108-01 in Patients With Solid Tumors" RSS

09:40 EDT 21st March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Safety Study of PLX108-01 in Patients With Solid Tumors" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Safety Study of PLX108-01 in Patients With Solid Tumors" on BioPortfolio

We have published hundreds of Safety Study of PLX108-01 in Patients With Solid Tumors news stories on BioPortfolio along with dozens of Safety Study of PLX108-01 in Patients With Solid Tumors Clinical Trials and PubMed Articles about Safety Study of PLX108-01 in Patients With Solid Tumors for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety Study of PLX108-01 in Patients With Solid Tumors Companies in our database. You can also find out about relevant Safety Study of PLX108-01 in Patients With Solid Tumors Drugs and Medications on this site too.

Showing "Safety Study PLX108 Patients With Solid Tumors" Clinical Trials 1–25 of 37,000+

Extremely Relevant

Safety Study of PLX108-01 in Patients With Solid Tumors

PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. These tumors include, but are not limited to, acute myelogenous leukemia (Flt3), gastrointestinal stromal tumor and neurofibromatosis-1 (Kit), and glioma, breast cancer, p...


Relevant

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.


Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

This aim of study to assess the safety and tolerability of SHR7390 and to define the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors. To evaluate the pharmacokinetics of SHR7390 in patients with advanced solid tumors. To study the effects of food on the pharmacokinetic parameters of SHR7390. To assess the antitumor activity of SHR7390 in patients with advanced solid tumors preliminarily and recommend reasonable dosage regimen for the follow-...

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors. In part 1, multiple dose levels of MSC-1 in patients with Advanced Solid Tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in ...

A Phase I Study of SC10914 in Patients With Advanced Solid Tumors

SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with advanced solid tumors. Furthermore, the safety and efficacy of SC10914 in patients with advanced solid tumors and negative expression of ATM or BRCA1 or BRCA2 mutation will be evaluated in expanded cohorts to establish the Recommended Phase 2 Dose(RP2D...

Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

The purpose of this study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab-paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel in patients with solid tumors. The structure for the study is a single arm, non-randomized, open-label, multicenter trial with no control group. The study will be conducted at approximately 8 sites with app...

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

A Study of PD1 Combined With Dc-nk in the Treatment of Solid Tumors

clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

First in Human Study of IBI310 in Treatment of Patients With Advanced Solid Tumors

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310 in patients with advanced solid tumors.

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.

Kanitinib in Treating Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

A Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese patients with advanced solid tumors.

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.

CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.


More From BioPortfolio on "Safety Study of PLX108-01 in Patients With Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement